🇺🇸 FDA
Patent

US 7273851

Tri-peptide hepatitis C serine protease inhibitors

granted A61KA61K38/00

Quick answer

US patent 7273851 (Tri-peptide hepatitis C serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Sep 20 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Sep 25 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 20 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K38/00